Home › Products › Oncology › Spnib 50mg Tablet
Spnib 50mg Tablet
Salt Composition: DASATINIB
- Manufacturer: ZYDUS CADILA
- Pack Size: 60 TABLET(s) IN A BOTTLE
- Dosage Form: TABLET
- Strength: 50MG
- Prescription Required
- Storage: Store protected from light at a temperature not exceeding 30c.
₹3153.00₹3503.44
Inclusive of all taxes
Product Introduction
Spnib 50mg Tablet contains Dasatinib as its active ingredient. It is prescribed for adults and children aged one year and older to treat Chronic Myeloid Leukemia (CML). It is also indicated for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients who are resistant or intolerant to other treatments. Chronic Myeloid Leukemia is a type of blood cancer caused by genetic changes involving the Philadelphia chromosome, leading to excessive production of abnormal white blood cells. Acute Lymphoblastic Leukemia (ALL) is a rapidly progressing blood cancer, most commonly seen in children, in which immature lymphocytes multiply uncontrollably. The Spnib 50mg Tablet composition contains Dasatinib, and the Spnib 50mg dosage is determined by your doctor based on your medical condition, stage of disease, and response to treatment.
The Spnib 50mg Tablet uses include the effective management of CML and Ph+ ALL under specialist supervision.
Uses
Spnib 50mg tablet is indicated for the following conditions Children and adults with chronic myeloid leukemia. Adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance to prior therapy.
How it works
Spnib 50mg tablet works by preventing the abnormal protein from signaling the growth of cancer cells. This aids in preventing or reducing the spread of cancer cells.
How to Use
Take the tablet with or without food at the same time each day. Do not break, crush or chew the tablet. Your doctor will decide the dose and frequency of Spnib 50mg tablet administration based on your disease severity and other factors. Do not stop taking the tablet without consulting your healthcare professional.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. spnib 50 mg side effects are Serious Unusual bleeding or bruising Rapid heart rate Changes in consciousness or speech Breathlessness and swelling all over the body Fever or signs of infection Fluid retention Heart problems Myelosuppression Severe allergic reaction Common Diarrhea Headache Cough Rash Nausea, tiredness, vomiting Muscle pain, weakness Low appetite High or low BP
Expert Tips
Use effective contraceptives for both men and women while taking Spnib 50mg tablet and for 30 days after the last dose. Monitor your blood pressure regularly during treatment. Inform your doctor immediately if you notice blood in your urine or stools. If you are taking an antacid, take it 2 hours before or 2 hours after taking this tablet.
References
- Bristol-Myers Squibb Pharma, Electronic Medicines Compendium (EMC), [Revised on Mar 2022] [Accessed on 1st Dec 2022], https://www.medicines.org.uk/emc/files/pil.7745.pdf
- Bristol-Myers Squibb Company, [Revised on Jun 2021] [Accessed on 1st Dec 2022], https://packageinserts.bms.com/ppi/ppi_sprycel.pdf
- H.G. Watson, J.I.O. Craig, L.M. Manson, Blood disease, Davidsonâs Principles and Practice of Medicine, 22nd Edition, 2014, 989-1056.
- Edward Chu, Cancer Chemotherapy, Langeâs Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.
Safety Advice
Pregnancy: unsafe Spnib 50mg tablet is not recommended during pregnancy unless necessary. Your physician will discuss the potential risk during pregnancy. Women should use effective birth control during treatment and 30 days after the final dose.
Lungs: Consult your doctor It is unknown whether Spnib 50mg tablet is safe to administer in patients with lung problems. Inform your physician if you have any lung disease before starting the treatment.
Breastfeeding: unsafe It is not recommended to breastfeed while taking Spnib 50mg tablet as it is unknown whether this medication passes into breast milk. You should not breastfeed during treatment and for 2 weeks after your final dose.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.